A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND Surrogates are frequently used in cancer medicine as the end-point of clinical trials and as the basis of United States Food and Drug Administration approvals, but they do not always represent outcomes that are important for patients. We aim to build upon previous umbrella reviews of surrogate validation studies by identifying and examining all meta-analyses of randomised controlled trials that evaluate the strength of correlation between overall survival (OS) and surrogate markers. METHODS Google Scholar and PubMed were searched by two independent reviewers for all eligible meta-analyses of randomised controlled trials examining the correlation between a surrogate end-point and OS in medical oncology. Included studies were trial-level (level-1) meta-analyses of randomised controlled trials in cancer. Data abstracted include date of publication, tumour type, setting, trial set, number of studies included in the analysis, dates of included publications, correlation coefficients and method to determine the correlation coefficient. RESULTS Seventy-eight articles met the inclusion criteria and reported correlations in 89 settings. Eleven (12%) of these validation studies found only high correlation(s), while nine (10%) settings showed a moderate-only correlation. Thirty-four (38%) reported only low correlation(s). Thirty-five (39%) reported correlations of different strengths, depending on surrogate marker used and test of correlation. CONCLUSIONS In this large, umbrella analysis of surrogate validation studies, we found most surrogates in oncology had low or modest correlation with OS, which suggests that caution should be used when making conclusions based on surrogate markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Oba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt270 · Cited by 168
Cited by
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Büchter, R. B., Weise, A., & Pieper, D. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01143-3 · Cited by 151
Hey, S. P., Gyawali, B., D’Andrea, E., Kanagaraj, M., Franklin, J. M., & Kesselheim, A. S. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz211 · Cited by 29
“Although PFS is believed to be a reliable surrogate measure for extending overall survival (OS) for some cancers, in other cancers, treatments may simply delay the time until a cancer progresses but still fail to improve OS (2).”
BackgroundResultInfluentialSelf-citationvan Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
“…recurrent/refractory osteosarcoma-specific/strata phase-II trials, but remained heterogeneous (type, definition, time point), reflecting the debate on the appropriate survival primary endpoint to be used as a surrogate marker of OS to get drugs approved, with PFS being increasingly used [85 – 87].”
Schnog, J. B., Duits, A. J., & Samson, M. J. (2024) · BJC Reports · doi:10.1038/s44276-024-00065-7 · Cited by 7
Metadata
- Authors
- Haslam, A., Hey, S. P., Gill, J., & Prasad, V.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 106
- Pages
- 196-211
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2902350957
- Cited by
- 209
- References
- 2
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.